Atlas Trials

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Clinical trial NCT03875313 · TERMINATED

Trial details

NCT number
NCT03875313
Sponsor
Calithera Biosciences, Inc
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast CancerColorectal CancerCRCRCCccRCC
Start date
2019-05-20
Primary completion
2020-07-29
Enrollment
33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.